Please assess the completion status of the following clinical trial:

Trial Title: A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Medically stable based on physical examination, medical history, vital signs, electrocardiogram (ECG) at screening~* Chronic hepatitis B virus (HBV) infection with documentation at least 6 months prior to screening~* Hepatitis B surface antigen (HBsAg) greater than (\>) 100 International Units per Milliliter (IU/mL) at screening~* Body mass index (BMI) between 18.0 and 35.0 kilogram per meter square (kg/m\^2), extremes included~* Highly effective contraceptive measures in place for female participants of childbearing potential or male participants with female partners of childbearing potential~* Liver fibrosis stage 0-2 (Metavir) or Fibroscan less than (\<) 9 Kilopascal (kPa) at screening~Exclusion Criteria:~* Evidence of infection with hepatitis A, C, D or E virus infection or evidence of human immunodeficiency, virus type 1 (HIV-1) or HIV-2 infection at screening~* History or evidence of clinical signs/symptoms of hepatic decompensation including but not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal varices or any laboratory abnormalities indicating a reduced liver function as defined in the protocol~* Evidence of liver disease of non-HBV etiology~* Signs of hepatocellular carcinoma (HCC)~* Significant laboratory abnormalities as defined in the protocol at screening~* Participants with a history of malignancy within 5 years before screening~* Abnormal sinus rhythm or ECG parameters at screening as defined in the protocol~* History of or current cardiac arrhythmia or history or clinical evidence of significant or unstable cardiac disease~* Participants with any current or previous illness for which, in the opinion of the investigator and/or sponsor, participation would not be in the best interest of the participant~* History of or current clinically significant skin disease or drug rash~* Participants with known allergies, hypersensitivity, or intolerance to JNJ-3989 and JNJ 6379 or their excipients or excipients of the placebo content~* Contraindications to the use of entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF) per local prescribing information~* Participants who have taken any therapies disallowed per protocol~* Female participants who are pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 90 days after the last dose of study intervention~* Male participants who plan to father a child while enrolled~* Participants who had or planned major surgery, (example, requiring general anesthesia) or who have received an organ transplant~* Vulnerable participants (example, incarcerated individuals, individuals under a legal protection measure)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: JNJ-73763989 (medium dose) + JNJ-56136379 + NA (Type: EXPERIMENTAL): Participants will receive medium dose of JNJ-73763989 along with JNJ-56136379 and nucleos(t)ide analog (NA) treatment (either entecavir \[ETV\], tenofovir disoproxil fumarate \[TDF\], or tenofovir alafenamide \[TAF\]) up to 48 weeks.
- Arm 2: JNJ-73763989 (high dose) + Placebo + NA (Type: EXPERIMENTAL): Participants will receive high dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
- Arm 3: JNJ-73763989 (medium dose) + Placebo + NA (Type: EXPERIMENTAL): Participants will receive medium dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
- Arm 4: JNJ-73763989 (low dose) + Placebo + NA (Type: EXPERIMENTAL): Participants will receive low dose of JNJ-73763989 along with placebo for JNJ-56136379 and NA (either ETV, TDF, or TAF) up to 48 weeks.
- Arm 5: Placebo + JNJ-56136379 + NA (Type: EXPERIMENTAL): Participants will receive placebo for JNJ-73763989 and a fixed dose of JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.
- Arm 6 (Control): Placebo + Placebo + NA (Type: PLACEBO_COMPARATOR): Participants will receive placebo for JNJ-73763989 and placebo for JNJ-56136379 along with NA (either ETV, TDF, or TAF) up to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete